JMDC Inc. (4483) AI Stock Analysis

• Market Cap: ¥245.96B
• Dividend Yield: 0.43%
• Average Volume (3M): 294.26K
• Price to Earnings (P/E): 40.0
• Beta (1Y): 0.78
• Revenue Growth: 20.55%
• EPS Growth: 48.62%
• Country: JP
• Employees: 1,773
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 21.56
• Shares Outstanding: 65,416,610
• 10 Day Avg. Volume: 384,370
• 30 Day Avg. Volume: 294,260
• PEG Ratio: 0.45
• Price to Book (P/B): 2.31
• Price to Sales (P/S): 4.32
• P/FCF Ratio: 14.35
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,700.00
• Price Target Upside: 21.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: ¥3,993.00 ▼(-14.99% Downside)

JMDC Inc.'s overall stock score is driven by strong financial performance, which is the most significant factor. However, technical analysis indicates bearish momentum, and the valuation suggests the stock may be overvalued. These factors combined result in a moderate overall score, reflecting both the company's solid financial health and current market challenges.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and successful product adoption, reinforcing JMDC's position in the healthcare data analytics sector.

Profitability Margins

Strong profitability margins reflect efficient operational management and pricing power, supporting sustainable long-term financial health.

Balance Sheet Health

A balanced capital structure with moderate leverage enhances financial stability and flexibility, enabling JMDC to invest in growth opportunities.

Negative Factors

Free Cash Flow Decline

A decline in free cash flow growth can limit JMDC's ability to reinvest in the business and manage unexpected expenses, potentially impacting future growth.

Cost Pressures

Rising cost pressures could erode profit margins over time, challenging JMDC's ability to maintain its current profitability levels.

Cash Generation Efficiency

Lower cash generation efficiency relative to net income may indicate challenges in converting earnings into cash, affecting liquidity and investment capacity.

JMDC Inc. Business Overview & Revenue Model

Company Description

JMDC Inc. provides medical statistics data services in Japan. The company operates through three segments: Healthcare-Big Data, Telemedicine, and Dispensing Pharmacy Support. It offers medical field big data services; life insurance field big data services; support services for health insurance associations and local government health services; health data platform; and medical institution support services. The company also provides remote image interpretation matching services and ASP services for remote image interpretation system; and develops and sells business systems for dispensing pharmacies. It serves health insurance unions, pharmaceutical companies, life and non-life insurance companies, research institutions, etc. The company was incorporated in 2002 and is headquartered in Tokyo, Japan.

How the Company Makes Money

JMDC Inc. generates revenue through several key streams, including subscription fees for its data analytics platform, consulting services, and partnerships with healthcare organizations and insurance companies. The subscription model allows clients to access JMDC's comprehensive health data analytics tools, which help them make informed decisions based on real-time data. Additionally, JMDC earns income by providing tailored consulting services to optimize healthcare operations and improve patient outcomes. Significant partnerships with various healthcare stakeholders further enhance JMDC's revenue potential, as they often lead to collaborative projects and expanded service offerings.

JMDC Inc. Financial Statement Overview

Summary

JMDC Inc. exhibits strong financial performance with consistent revenue growth and solid profitability margins. The balance sheet is stable with manageable leverage, although the recent decline in free cash flow growth warrants attention. The company is well-positioned in the healthcare information services industry, with a solid foundation for future growth.

Income Statement

JMDC Inc. demonstrates strong revenue growth with a TTM increase of 5.52%, supported by healthy gross and net profit margins of 57.16% and 17.43%, respectively. The EBIT and EBITDA margins are robust at 20.94% and 27.63%, indicating efficient operational management. The company has consistently grown its revenue over the years, showcasing a positive growth trajectory.

Balance Sheet

The balance sheet reflects a stable financial position with a moderate debt-to-equity ratio of 0.60, indicating manageable leverage. The return on equity is decent at 9.88%, suggesting effective use of equity to generate profits. The equity ratio stands at 52.23%, highlighting a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth by 17.14% in the TTM, which could be a concern. However, the operating cash flow to net income ratio is healthy at 1.62, and the free cash flow to net income ratio is strong at 85.57%, indicating good cash generation relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	45.60B	41.72B	32.38B	27.81B	21.81B	16.77B
Gross Profit	25.39B	23.85B	19.25B	15.86B	12.59B	9.62B
EBITDA	12.52B	11.53B	9.23B	7.98B	6.51B	4.88B
Net Income	7.46B	7.28B	4.61B	4.27B	3.25B	2.48B
Balance Sheet
Total Assets	152.67B	143.02B	122.45B	98.57B	62.06B	57.85B
Cash, Cash Equivalents and Short-Term Investments	37.45B	32.18B	14.47B	22.78B	13.19B	19.90B
Total Debt	52.48B	46.89B	37.83B	20.40B	17.80B	19.45B
Total Liabilities	72.78B	64.54B	51.77B	34.04B	30.89B	29.60B
Stockholders Equity	79.48B	78.02B	70.59B	64.54B	31.18B	28.25B
Cash Flow
Free Cash Flow	9.58B	12.57B	-2.27B	2.12B	2.49B	952.00M
Operating Cash Flow	10.76B	14.69B	-17.00M	4.06B	3.81B	3.18B
Investing Cash Flow	-3.95B	-3.47B	-24.86B	-22.77B	-8.10B	-9.08B
Financing Cash Flow	1.59B	6.48B	16.58B	28.30B	-2.41B	18.11B

JMDC Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4697.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4483, the sentiment is Negative. The current price of 4697 is above the 20-day moving average (MA) of 3970.00, above the 50-day MA of 4343.86, and above the 200-day MA of 3824.80, indicating a bearish trend. The MACD of -162.51 indicates Positive momentum. The RSI at 38.84 is Neutral, neither overbought nor oversold. The STOCH value of 19.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4483.

JMDC Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3649	79 Outperform	¥23.49B	19.73	―	1.74%	-2.05%	-9.92%
2175	68 Neutral	¥118.21B	15.33	―	2.11%	7.27%	13.10%
4480	67 Neutral	¥76.44B	47.30	8.79%	―	31.95%	-40.95%
4483	61 Neutral	¥245.96B	39.98	―	0.43%	20.55%	48.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3902	43 Neutral	¥65.75B	-152.46	―	0.39%	6.17%	-8918.66%

JMDC Inc. Corporate Events

JMDC Inc. Reports Strong Financial Growth in First Half of Fiscal Year 2026

JMDC Inc. reported a significant increase in its financial performance for the first half of the fiscal year ending March 31, 2026, with a 24.4% rise in revenue and a 27.7% increase in operating profit compared to the previous year. The company’s strategic decision to classify its dispensing pharmacy support business as discontinued operations has streamlined its focus on core operations, potentially strengthening its market position and benefiting stakeholders.